Prophylactic and/or Therapeutic Drug for Diabetic Nephropathy
AssigneesHubit Genomix, Inc., Fuso Pharmaceutical Industries, Ltd.
InventorsToshio Doi, Tatsuya Tominaga, Yui Fujita
Life of this patent
Estimating the term…
Abstract
The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RARγ agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.
Claims18
(canceled)
The method according to claim 14, wherein the RARγ agonist is at least one compound selected from the group consisting of palovarotene, 3-fluoro-4-(2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydronaphthalen-2-yl)acetamido)benzoic acid, 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid, esters thereof and salts thereof.
The method according to claim 14, wherein diabetic nephropathy is derived from type 2 diabetes.
(canceled)
(canceled)
The method according to claim 16, wherein the RARγ agonist is at least one compound selected from the group consisting of palovarotene, 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid esters thereof and salts thereof.
(canceled)
The method according to claim 17, wherein the RARγ agonist is at least one compound selected from the group consisting of palovarotene, 3-fluoro-4-(2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydronaphthalen-2-yl)acetamido)benzoic acid, esters thereof and salts thereof.
(canceled)
The method according to claim 18, wherein the RARγ agonist is at least one compound selected from palovarotene, esters thereof and salts thereof.
The method according to claim 18, which inhibits the expression of pSmad2/3 in the renal tubulointerstitial cells.
The method according to claim 18, wherein fibrosis in the renal tubulointerstitium is derived from diabetic nephropathy.
The method according to claim 14, which is to be administered orally or parenterally.
A method of treating diabetic nephropathy in a subject in need thereof, comprising
- administering an effective amount of an RARγ agonist to the subject.
A method of treating renal anemia in a subject in need thereof, comprising
- administering an effective amount of an RARγ agonist to the subject.
A method of suppressing expression of type IV collagen in mesangial cells, comprising
- contacting an RARγ agonist with the mesangial cells.
A method of suppressing expression of BMP4 in mesangial cells, comprising
- contacting an RARγ agonist with the mesangial cells.
A method of suppressing fibrosis in renal tubulointerstitium, comprising
- contacting an RARγ agonist with the renal tubulointerstitium.
Dependencies are inferred from the claim text.